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T
here  have  been  considerable  advances  in  the 
technology of assessing real-time glucose levels in 
patients with diabetes. The first self-testing kit for 
measuring glucose in urine was developed in the 1940s. 
The advent of the capillary blood test strip followed in 
1956, and glucose meters in the 1970s and early 1980s.1 
The introduction of these latter devices meant that pa-
tients taking insulin had an option other than urine test-
ing for monitoring their glucose levels. Since then, glucose 
meters have become smaller and lighter, and the amount 
of blood required and time to get a result have decreased. 
These advances have facilitated the adoption of self-
monitoring of blood glucose levels as part of the routine 
care of diabetes managed with insulin. People with dia-
betes can obtain a quick and accurate reading of their 
blood glucose level and use this information to adjust 
their  insulin  to  reach  evidence-based  therapeutic  tar-
gets. In contrast, those whose type 2 diabetes is man-
aged  with  oral  hypoglycemic  therapy  typically  cannot 
adjust their treatment in response to a specific blood glu-
cose reading. Although blood glucose readings inform 
care providers on the effectiveness of prescribed treat-
ment regimens, the direct benefit of self-monitoring to 
the patient not taking insulin is unclear.
In  this  issue  of  Open  Medicine,  McIntosh  and  col-
leagues examine the efficacy of self-monitoring of blood 
glucose levels in patients with type 2 diabetes managed 
without insulin.2 Their rigorously conducted systematic 
review and meta-analysis of 21 studies showed that self-
monitoring resulted in a modest, significant reduction in 
hemoglobin  A1c  (HbA1c)  concentration  (weighted  mean 
difference –0.25%, 95% confidence interval [CI] –0.36% 
to –0.15%) compared with no self-monitoring. Subgroup 
analysis showed no significant difference between the 
results  from  randomized  controlled  trials  (RCTs)  that 
provided  patients  with  education  on  how  to  interpret 
and apply self-monitoring test results (weighted mean 
difference  –0.28%,  95%  CI  –0.47%  to  –0.08%)  com-
pared with RCTs that did not (weighted mean difference 
–0.22%, 95% CI –0.34% to –0.10%). The results did not 
change when the authors included only studies of higher 
quality (3 RCTs, weighted mean difference –0.21%, 95% 
CI –0.34% to –0.08%) or in the subgroup analysis that 
looked at frequency of self-monitoring per day, duration 
of  self-monitoring,  time  since  diabetes  diagnosis,  gly-
cemic control or type of oral hypoglycemic therapy used. 
McIntosh and colleagues sought to determine the opti-
mal frequency of self-monitoring; however, there were 
insufficient data available to assess this.
Similar to another recently published review,3 the re-
view by McIntosh and colleagues demonstrates that self-
monitoring of blood glucose levels results in a reduction 
in HbA1c concentration of 0.25%. Although a statistically 
significant result, it is unclear what it means clinically. A 
wealth of epidemiologic evidence has shown significant 
reductions  in  micro-  and  macrovascular  complication 
rates with decreasing HbA1c levels, with some showing 
a relative risk reduction of up to 18% in cardiovascular 
events with every 1% decrease in HbA1C level.4 However, 
interventional trials designed to test whether intensive 
glucose-lowering strategies benefit patients with type 2 
diabetes have shown mixed and somewhat modest bene-
fits. The ACCORD, ADVANCE and VADT studies and the 
10-year follow-up data from the UKPDS trial have shown 
that the degree of benefit related to lowering HbA1c with 
respect  to  macrovascular  outcomes  likely  depends  on several factors, including the duration of diabetes, the 
degree  of  dysglycemia  and  perhaps  the  choice  of  oral 
therapy used.5–8 In absolute terms, the number of events 
prevented by lowering the HbA1c concentration by 0.25% 
would appear to be quite small given the cost of self-
monitoring of blood glucose. In fact, a recent economic 
analysis  conducted  by  Cameron  and  colleagues  show 
ed that the absolute risk reduction in micro- and macro-
vascular disease associated with 40 years of self-mon-
itoring  of  blood  glucose  among  people  with  diabetes 
managed without insulin was rather small.3 The number 
needed to treat to prevent 1 diabetes-related complica-
tion ranged from 228 (for heart failure) to 1299 (for end-
stage renal disease). Although the direct benefits to the 
person performing the self-monitoring may be under-
whelming,  the  downside  is  clear:  self-monitoring  is   
uncomfortable, inconvenient and costly.9
Further trials comparing self-monitoring and no self-
monitoring are not needed (although there are several 
published protocols for proposed studies). What is need-
ed is clear evidence on the optimal clinical application of 
self-monitoring. Patients with type 2 diabetes are a clin-
ically heterogeneous population. Although the benefit of 
self-monitoring to the entire population is small, there 
are  likely  subgroups  who  do  benefit  from  testing.  We 
must also consider that self-monitoring of blood glucose 
is not cheap and has been found to be cost-inefficient.3 
Despite the paucity of strong evidence for clinical or cost 
effectiveness, a recent study by Gomes and colleagues 
showed that overall use of self-monitoring increased by 
almost 250% from 1997 to 2008 in Ontario.10 The study 
also showed that 60% of patients taking diabetes medi-
cations not known to cause hypoglycemia and 30% of pa-
tients who did not use any diabetes drugs were dispensed 
blood glucose test strips.10 Recognizing the tremendous 
cost of self-monitoring, Gomes and colleagues used deci-
sion analysis modelling to propose several blood glucose 
self-monitoring strategies based on the type of therapy 
patients were receiving (e.g., lifestyle modification, oral 
hypoglycemic therapy, insulin), presuming that patients 
taking insulin and those at risk for hypoglycemia may 
receive the most benefit from self-monitoring. They con-
cluded  that  unlimited  coverage  of  self-monitoring  for 
those taking insulin and limited, strategic testing among 
those not taking insulin would significantly reduce the 
costs associated with self-monitoring and may not alter 
clinical outcomes.10 This conclusion is based on simula-
tion modelling, which has inherent limitations. However, 
tailored strategies for self-monitoring of blood glucose 
need to be studied prospectively to determine their im-
pact on both clinical outcome and cost. 
So where does that leave us? Self-monitoring of blood 
glucose appears to improve glycemic control in patients 
with type 2 diabetes managed without insulin. But does 
this  translate  into  better  patient  outcomes,  especially 
when we factor in the pain, inconvenience and cost of 
self-monitoring  to  patients?  Do  all  patients  with  type 
2 diabetes managed without insulin need to engage in 
self-monitoring? Probably not, but we still lack import-
ant information on how to use this technology effectively 
and efficiently and who will benefit the most. Ultimately 
we require prospective trials that examine under what 
conditions to make best use of this tool so that a broad, 
indiscriminate approach can be avoided.
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